Research
Energy balance
In clinical practice, GLP-1a therapy was associated with more modest reductions in weight and HbA1c than shown in prior RCTs.
Practitioners should be aware that real-world outcomes may differ from clinical trial results.
StrongQualifiesmedium confidence
In clinical practice, GLP-1a therapy was associated with more modest reductions in weight and HbA1c than shown in prior RCTs.
Why this rating
Based on study design from abstract.
Source
Glucagon-like peptide-1 receptor agonist therapy effects on glycemic control and weight in a primary care clinic population
E. Paleček et al. · Journal of Investigative Medicine · 2024
DOI 10.1177/10815589241270427
cohort · n=693Cited 5×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- GLP-1a therapy was associated with a mean change in HbA1c of −1.00% (±2.07) in treated patients compared to −0.83% (±1.92) in those without GLP-1a therapy.Strong
- GLP-1a therapy was associated with a mean change in body mass index (BMI) of −0.83 kg/m2 in treated patients compared to −0.70 kg/m2 in those without GLP-1a therapy.Strong
Related findings · Energy balance
- Achieving a total body weight loss of 10-15% (or >10-15 kg) through Total Diet Replacement (TDR) induces remission of Type 2 Diabetes in individuals with short-duration disease.Strong
- Bariatric surgery is superior to medical management alone for inducing significant long-term weight loss, remission of type 2 diabetes, and reduction in mortality for patients with BMI ≥ 40 or ≥ 35 with comorbidities.Strong
- Achieving type 2 diabetes remission requires significant weight loss (≥15 kg) via major caloric restriction, independent of macronutrient composition.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →